Sangamo Therapeutics (SGMO) Stock Price, Quote & News

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 970 6000

Website: www.sangamo.com

Address:

501 Canal Blvd, Richmond, United States

Vikingsstrade Oct. 4 at 6:06 PM

$AEO $COMM $SGMO $SNY Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.

0 · Reply

Imv85 Oct. 4 at 2:45 PM

$SGMO I’m traveling this weekend. I’ve just arrived at the hotel and in the conference room there’s a seminar on Fabry hosted by Sanofi. Sometimes you just need a sign…

3 · Reply

andre1153 Oct. 4 at 2:16 PM

$SGMO 🧬 SGMO — Catalyst Stack (October 2025) Fabry STAAR Data Confirmed • FDA accepted eGFR slope at 52 weeks as basis for Accelerated Approval • SGMO intends to file BLA in 2026 • Presented at ICIEM 2025 (Kyoto) on Sept 4 Breakout Price Action • Broke out of $0.5610–$0.5650 zone • Hit $0.7259 on Sept 30 — highest since June 27 • Holding coil at $0.67 with elevated volume Insider & Institutional Positioning • Jacobs Levy Equity Management bought 555K shares (Sept 15) • GSA Capital Partners increased position (Aug 4) • ⚠️ Goldman Sachs sold 651K shares (Sept 25) Government Tailwinds • FDA tone favors rare disease acceleration • SEC deregulation boosts BD attractiveness • Trump’s 100% pharma import tariff now active — SGMO is exempt • Powell’s dovish tone supports biotech risk-on flow BD/M&A Potential • SGMO’s Fabry program is de-risked and scalable • No current BD deal filed — traders watching for 8-K or insider buying • Sympathy setups: APLT, BPMC, BMRN

0 · Reply

theflagbearer Oct. 4 at 2:13 PM

$SGMO whats the catalyst here, new to this stock, anyone wanna share DD

1 · Reply

GothamGirl Oct. 4 at 4:29 AM

$SGMO @dongknotts

2 · Reply

GothamGirl Oct. 4 at 4:03 AM

$SGMO @dongknots Nice try.

2 · Reply

Top_Dog_Pro_Trader Oct. 4 at 1:23 AM

$SGMO At least you admit your analysis is crap, doesn’t it follow your conclusion would also be crap?

2 · Reply

TwoThirdsProbablyDown Oct. 4 at 12:50 AM

$SGMO No CFO would voluntarily resign if a deal was less than 30 days away, arbitrarily giving up the reputational benefits of being the deal-maker. This does not bode well for my hopes and dreams of retiring by Columbus day.

2 · Reply

dongknotts Oct. 3 at 11:17 PM

$SGMO I think these guys are running the ATM this past week. The Fabry data seems solid for overall patient outcome but the FDA guideline for accelerated pathway wants a positive eGFR slope and unfortunately the ST-920 confidence interval contains 0, meaning the positive mean improvement reported by SGMO could have happened by chance and should be considered statistically insignificant and disregarded. Then they try some tricky meta-analysis to show their statistically insignificant data compares favorably to other treatments, that is not how things are done. SGMO is playing games and the Fabry data is probably not as compelling as they say which is why there is no partner. The 45 million outstanding warrants will create major resistant for any price over $0.75 so unless there is a major partnership announcement, that is top dollar and a good exit point. The risk of delisting is real and good luck selling shares if that happens.

6 · Reply

Swamp_Yankee Oct. 3 at 10:47 PM

$SGMO Wait till PETA sees this Sandy.

0 · Reply

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Aug 8, 2025, 2:53 PM EDT - 2 months ago

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 31, 2025, 4:05 PM EDT - 2 months ago

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Jun 24, 2025, 8:05 AM EDT - 3 months ago

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

May 12, 2025, 9:06 PM EDT - 5 months ago

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12, 2025, 6:26 PM EDT - 5 months ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12, 2025, 6:23 PM EDT - 5 months ago

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12, 2025, 4:00 PM EDT - 5 months ago

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 6, 2025, 4:35 PM EDT - 5 months ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 8:30 AM EDT - 5 months ago

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Apr 28, 2025, 4:31 PM EDT - 5 months ago

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 4, 2025, 2:57 PM EDT - 6 months ago

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Apr 3, 2025, 4:01 PM EDT - 6 months ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Mar 17, 2025, 6:29 PM EDT - 7 months ago

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:01 PM EDT - 7 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 4:05 PM EST - 7 months ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Feb 6, 2025, 8:05 AM EST - 8 months ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Jan 15, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Jan 14, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 9 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Jan 10, 2025, 10:00 AM EST - 9 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 9, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Jan 8, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Jan 7, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Jan 6, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Jan 5, 2025, 10:00 AM EST - 9 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Jan 2, 2025, 6:00 PM EST - 9 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Jan 2, 2025, 4:00 PM EST - 9 months ago

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Jan 2, 2025, 3:05 PM EST - 9 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Jan 2, 2025, 10:15 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation

Dec 31, 2024, 12:01 PM EST - 9 months ago

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Dec 31, 2024, 11:22 AM EST - 9 months ago

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

PFE

Vikingsstrade Oct. 4 at 6:06 PM

0 · Reply

Imv85 Oct. 4 at 2:45 PM

$SGMO I’m traveling this weekend. I’ve just arrived at the hotel and in the conference room there’s a seminar on Fabry hosted by Sanofi. Sometimes you just need a sign…

3 · Reply

andre1153 Oct. 4 at 2:16 PM

0 · Reply

theflagbearer Oct. 4 at 2:13 PM

$SGMO whats the catalyst here, new to this stock, anyone wanna share DD

1 · Reply

GothamGirl Oct. 4 at 4:29 AM

$SGMO @dongknotts

2 · Reply

GothamGirl Oct. 4 at 4:03 AM

$SGMO @dongknots Nice try.

2 · Reply

Top_Dog_Pro_Trader Oct. 4 at 1:23 AM

$SGMO At least you admit your analysis is crap, doesn’t it follow your conclusion would also be crap?

2 · Reply

TwoThirdsProbablyDown Oct. 4 at 12:50 AM

2 · Reply

dongknotts Oct. 3 at 11:17 PM

6 · Reply

Swamp_Yankee Oct. 3 at 10:47 PM

$SGMO Wait till PETA sees this Sandy.

0 · Reply

andre1153 Oct. 3 at 9:36 PM

$SGMO ouch we going the wrong way…

2 · Reply

Swamp_Yankee Oct. 3 at 9:19 PM

$SGMO Sandy Blowmax. What in the world are you up to?

1 · Reply

wavridr Oct. 3 at 9:02 PM

$SGMO wtf is this shit. New LOD in AH?! 🤬

1 · Reply

Newtimmy Oct. 3 at 8:56 PM

$SGMO Sandblaster, which way did our deal go

0 · Reply

Top_Dog_Pro_Trader Oct. 3 at 7:12 PM

$SGMO Silent Sniper, where have you been? The FDA just released there new process for Gene approvals. Very positive for SGMO IMO!

1 · Reply

MarketILF Oct. 3 at 6:43 PM

$SGMO waiting for the buyers into the close just like every Friday

0 · Reply

biotech Oct. 3 at 6:18 PM

What The... there will be news next week ... $SGMO Presentation: Gene Therapy on the #Fast #Track: CMC Perspectives on Readiness, Risk, and Opportunities with #accelerated BLA and #Launch buy all you can today ... JUST IMHO

1 · Reply

biotech Oct. 3 at 6:11 PM

$SGMO #Astellas there too talking about partnerships + strategic choices ... tech transfer ... How #partnerships are evolving to meet compliance requirements for novel modalities Focusing on integrating key GCP-related processes, systems and personnel #early in the M&A process

1 · Reply

biotech Oct. 3 at 5:58 PM

$SGMO Sandeep Yadav VP Technical Development I Clinical CMC Strategy I #Commercial Product Strategy speaking next week at fierce biotech week

0 · Reply

SilentSniper Oct. 3 at 5:44 PM

$SGMO Big question for us to answer will be since the August call has the genomic medicine environment in the US changed or it still faces regulatory, reimbursement, and perception headwinds; and has the FDA’s consistency (or lack thereof) still a risk in partner evaluation..As per Sandy Potential partners have no doubt about the science and the data they been dragging this long for above reasons..what evidence have we seen lately (approvals and partnerships in genomic medicine space) that gives us confidence that the deal will materialize soon

3 · Reply

biotech Oct. 3 at 5:39 PM

$SGMO $VYGR

0 · Reply

biotech Oct. 3 at 5:38 PM

$SGMO

0 · Reply

Market Cap	206.04M
Revenue (ttm)	57.80M
Net Income (ttm)	-97.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-169.45%
Debt to Equity Ratio	0.00

Volume	3,569,400
Avg Vol	5,664,196
Day's Range	N/A - N/A
Shares Out	301.71M
Stochastic %K	65%
Beta	1.22
Analysts	Strong Sell
Price Target	$4.10